XASE
RVP
Market cap19mUSD
Oct 08, Last price
0.66USD
1D
-4.17%
1Q
-3.36%
Jan 2017
-28.82%
IPO
-93.54%
Name
Retractable Technologies Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Retractable Technologies, Inc. is a medical device company focused on the innovation, production, and sale of secure medical instruments, predominantly syringes, for the healthcare sector. Their reach extends across the United States, the broader North and South American continents, and other international territories. The company's diverse product range includes a variety of safety-engineered items such as VanishPoint insulin, tuberculin, and allergy antigen syringes, as well as Patient Safe syringes and Luer Caps. They also offer small diameter tube adapters, blood collection tube holders, allergy trays, and IV safety catheters. Further offerings feature VanishPoint blood collection sets, EasyPoint needles, and VanishPoint autodisable syringes. Distribution of these products occurs through a combination of general and specialized distributors, international partners, and a dedicated direct sales network. Founded in 1994, the company's main operations are headquartered in Little Elm, Texas.
Key people
Thomas Shaw
Chairman of the Board, President, Chief Executive Officer, Founder
Michele Larios
Vice President, General Counsel, Secretary
John Fort
Chief Financial Officer, Vice President, Treasurer, Director · since 2022
Walter Bigby
Independent Director · since 2012
Darren Findley
Independent Director · since 2017
Marco Laterza
Independent Director · since 2005
Amy Mack
Independent Director · since 2007
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||